Prague, Czech Republic – 28 June 2023 – HOYA Vision Care, a leader in optical technology innovation, was delighted to be a Silver Sponsor of the European Society of Ophthalmology Congress (SOE 2023) that took place 15–17 June 2023 in Prague, Czech Republic. This year’s SOE 2023 hosted a multi-specialty in-person meeting, delivering a world class scientific programme, offering symposia, workshops, live surgery, debates, mystery cases and updates on all topics.
As part of its commitment to share scientific knowledge and professional insights, and provide innovative solutions to address the growing problem of myopia progression in children, HOYA Vision Care hosted a symposium, Lighting the way: new evidence and advances in myopia management, where leading experts discussed the role of light exposure in myopia, announced the new additions to the MiYOSMART portfolio – MiYOSMART sun spectacle lenses and shared the latest results on the role of Defocus Incorporated Multiple Segments (DIMS) spectacle lenses in combination treatment in myopia management.
With growing interest and evidence about the protective effects of outdoor time and daylight on myopia development and its progression in children, both in the ophthalmology practice and in scientific literature,1–5 Professor Behar-Cohen, Professor at Cochin Hospital, Paris Descartes University, France, focused her talk on the researched benefits and risks associated with light exposure on myopic eyes, further highlighting the physical and biological role of light in vision.
Dr. Andrea Lembo, from the University Hospital San Giuseppe Multimedica in Milan, Italy, discussed the effect of the combination treatment of DIMS spectacle lenses and atropine on Caucasian eyes. Dr Lembo shared his practical experience by presenting the results of an observational, non-randomized study conducted in Italy, which included 146 young patients aged between 6 and 18 years with myopia progression. There were three treatment groups within the study — 0.01% low dose atropine once a day alone, MiYOSMART spectacle lenses alone and a combination treatment with both 0.01% low dose atropine and MiYOSMART spectacle lenses –revealed a reduction in myopia progression, taking into account spherical equivalent refraction and axial elongation, as well as the subjective worsening of visual acuity.6
Dr. Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care, explained the DI.M.S. Technology behind the MiYOSMART spectacle lens and presented the findings of the six-year follow-up clinical study, the longest clinical study conducted on a myopia management spectacle lens. Further, the launch of the new MiYOSMART sun solution were presented – MiYOSMART Chameleon, photochromic spectacle lenses; and MiYOSMART Sunbird, polarized spectacle lenses – currently rolling out in 30 countries worldwide. These two new products provide protection from intense sunlight, while simultaneously slowing down myopia progression using the same D.I.M.S. Technology used in MiYOSMART clear spectacle lenses7–13 shown to slow myopia progression on average by 60% in children aged 8 to 13.14
Since its launch in 2018 until the end of 2022, over 4 million MiYOSMART spectacle lenses have been purchased by parents across the world.15 With the launch of the new MiYOSMART Chameleon and MiYOSMART Sunbird spectacle lenses, HOYA Vision Care will continue to help fight and control the growing problem of myopia around the world.
